Synthesis and inhibitory activity of N-acetylpyrrolidine derivatives on α-glucosidase and α-amylase

• Main Authors: Sompong Sansenya, Chankan Winyakul, Kesinee Nanok, Waya S Phutdhawong
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2020-01-01
• Series: Research in Pharmaceutical Sciences
• Subjects: α-glucosidase and α-amylase inhibitory activity; diabetes type 2; type 2 diabetes mellitus; n-acetylpyrrolidine.
• Online Access: http://www.rpsjournal.net/article.asp?issn=1735-5362;year=2020;volume=15;issue=1;spage=14;epage=25;aulast=Sansenya
• ISSN: 1735-5362; 1735-9414

Background and purpose: Carbohydrate hydrolysis enzymes including α-glucosidase and α-amylase are related to type 2 diabetes mellitus. The inhibiting of these enzymes might use for type 2 diabetes mellitus treatment. Experimental approach: N-substituted-acetylpyrrolidine linked with -benzyl- (N-(benzyl)-2-acetylpyrrolidine (4a)) and -tosyl- (N-(tosyl)-2-acetylpyrrolidine (4b)) were synthesized and evaluated for their pharmaceutical properties against a-glucosidase and a-amylase and free radical scavenging activity. The structures of 4a and 4b were determined through spectral studies (1H-NMR). Findings / Results: Both compounds 4a and 4b had highest inhibitory potential on a-glucosidase with the IC50 values of 0.52 ± 0.02 and 1.64 ± 0.08 mM, respectively. The kinetic investigation of 4a and 4b against a-glucosidase and a-amylase were functioned in mixed type inhibition. Moreover, both compounds are more likely to bind with the free enzyme than the enzyme-substrate complex based on the Ki < Ki’ on the a-glucosidase and a-amylase enzymes. Regarding the free radical scavenging, 4a had a higher capacity than 4b with IC50 values of 1.01 ± 0.010 mM for 4a and 1.82 ± 0.048 mM for 4b. Conclusion and implications: Our results indicated that a derivative of N-substitute-acetylpyrrolidine had high potential to inhibit a-glucosidase and a-amylase, and their free radical scavenging properties might be applied to the therapeutic care of patients with type 2 diabetes mellitus.